Literature DB >> 7921721

Cannabis consumption as a prognostic factor in schizophrenia.

M J Martinez-Arevalo1, A Calcedo-Ordoñez, J R Varo-Prieto.   

Abstract

Data were analysed from 62 schizophrenic patients between 18 and 30 years of age, treated at the community mental health centres in Navarra, who had relapsed and then completed a one-year follow-up study. Factors influencing the course of illness during follow-up were: continuing cannabis consumption; previous cannabis intake; non-compliance with treatment; and stress.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7921721     DOI： 10.1192/bjp.164.5.679

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  13 in total

Review 1.  Cannabis and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

2.  Cannabis related psychiatric syndromes: a selective review.

Authors:  D Basu; A Malhotra; V K Varma
Journal:  Indian J Psychiatry       Date:  1994-07       Impact factor: 1.759

3.  Psychosis in Afro-Caribbean people. Further data should have obtained.

Authors:  N B Purandare; P N Joshi
Journal:  BMJ       Date:  1996-05-04

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome.

Authors:  A M Auther; D McLaughlin; R E Carrión; P Nagachandran; C U Correll; B A Cornblatt
Journal:  Psychol Med       Date:  2012-04-30       Impact factor: 7.723

6.  GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia.

Authors:  David W Volk; David A Lewis
Journal:  Curr Neuropharmacol       Date:  2005-01       Impact factor: 7.363

Review 7.  Cannabis-associated psychosis: current status of research.

Authors:  F Markus Leweke; Christoph W Gerth; Joachim Klosterkötter
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

9.  Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.

Authors:  Patrik Roser; Jürgen Gallinat; Gordon Weinberg; Georg Juckel; Inge Gorynia; Andreas M Stadelmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-02-17       Impact factor: 5.270

10.  The impact of cannabis use on clinical outcomes in recent onset psychosis.

Authors:  Christine Barrowclough; Lynsey Gregg; Fiona Lobban; Sandra Bucci; Richard Emsley
Journal:  Schizophr Bull       Date:  2014-07-09       Impact factor: 9.306
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.